{"denoms":[{"counts":[{"groupId":"BG000","value":"487"},{"groupId":"BG001","value":"489"},{"groupId":"BG002","value":"976"}],"units":"Participants"}],"groups":[{"description":"Participants received 200 mg pembrolizumab (2 mg/kg for a maximum of 200 mg in pediatric participants) by intravenous (IV) infusion once every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to \\~1 year) in Part 1. Participants who completed the initial treatment of 17 cycles of pembrolizumab and experienced disease recurrence may have been eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \\~2 years) in Part 2.","id":"BG000","title":"Pembrolizumab"},{"description":"Participants received saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to \\~1 year) in Part 1. Participants who completed the initial treatment of 17 cycles of placebo and experienced disease recurrence may have been eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \\~2 years) in Part 2.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.6","value":"59.0"},{"groupId":"BG001","spread":"13.3","value":"59.6"},{"groupId":"BG002","spread":"12.9","value":"59.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"387"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"300"},{"groupId":"BG001","value":"289"},{"groupId":"BG002","value":"589"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"79"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"390"},{"groupId":"BG001","value":"409"},{"groupId":"BG002","value":"799"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"98"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"435"},{"groupId":"BG001","value":"439"},{"groupId":"BG002","value":"874"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"87"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"T3a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"401"}]}],"title":"T3b"},{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"229"}]}],"title":"T4a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"344"}]}],"title":"T4b"}],"description":"Participants were stratified into T stages of melanoma, as defined by tumor thickness and ulceration, based on the American Joint Committee on Cancer (AJCC) 8th edition. The T stages were defined as follows: T3a: \\>2.0 - 4.0 mm thickness without ulceration; T3b: \\>2.0 - 4.0 mm thickness with ulceration; T4a: \\>4.0 mm without ulceration; T4b: \\>4.0 mm with ulceration.","paramType":"COUNT_OF_PARTICIPANTS","title":"Melanoma Primary Tumor (T) Stage","unitOfMeasure":"Participants"}]}